Moderna presented a promising cancer vaccine

Moderna and Merck's jointly developed cancer vaccine shows promise in melanoma treatment, reducing recurrence by 42% in clinical trials. The mRNA technology used is similar to that of COVID vaccines. Researchers are investigating its effectiveness against other difficult-to-treat cancers, such as pancreatic and brain tumors.